First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 805.7 INR -1.14% Market Closed
Updated: Apr 29, 2024
Section:
 

Relative Value

The Relative Value of one GLS stock under the Base Case scenario is 693.24 INR. Compared to the current market price of 805.7 INR, Glenmark Life Sciences Ltd is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLS Relative Value
Base Case
693.24 INR
Overvaluation 14%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

4.2
P/S
P/S
Price to Sales
4.2
vs History
8
vs Industry
30
Median 3Y
2.6
Median 5Y
2.6
Industry
2.4
Forward
4.1
More Details
19
P/E
P/E
Price to Earnings
19
vs History
8
vs Industry
26
Median 3Y
13.1
Median 5Y
13.1
Industry
22.9
Forward
19.2
More Details
21.7
P/OCF
P/OCF
Price to OCF
21.7
vs History
14
vs Industry
21
Median 3Y
12.2
Median 5Y
12.2
Industry
17.1
More Details
30.9
P/FCFE
P/FCFE
Price to FCFE
30.9
vs History
23
vs Industry
18
Median 3Y
23.2
Median 5Y
23.2
Industry
23.2
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
5
vs Industry
18
Median 3Y
3
Median 5Y
3
Industry
2.1
More Details
4
EV/S
EV/S
Enterprise Value to Sales
4
vs History
8
vs Industry
31
Median 3Y
2.4
Median 5Y
2.4
Industry
2.6
Forward
3.9
More Details
7.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.1
vs History
8
vs Industry
31
Median 3Y
4.6
Median 5Y
4.6
Industry
5.1
More Details
12.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.6
vs History
8
vs Industry
29
Median 3Y
8.1
Median 5Y
8.1
Industry
13.6
Forward
13
More Details
13.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.5
vs History
8
vs Industry
33
Median 3Y
8.5
Median 5Y
8.5
Industry
17
Forward
13.6
More Details
20.8
EV/OCF
EV/OCF
Enterprise Value to OCF
20.8
vs History
14
vs Industry
23
Median 3Y
11.2
Median 5Y
11.2
Industry
15.8
More Details
29.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
29.3
vs History
23
vs Industry
17
Median 3Y
21.5
Median 5Y
21.5
Industry
17.6
More Details
4.4
EV/IC
EV/IC
Enterprise Value to IC
4.4
vs History
5
vs Industry
19
Median 3Y
3.1
Median 5Y
3.1
Industry
1.9
More Details

Multiples Across Competitors

GLS Competitors Multiples
Glenmark Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Glenmark Life Sciences Ltd
NSE:GLS
98.7B INR 4.2 19 12.6 13.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
694.9B USD 20.4 132.6 59.9 68.8
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 17.1 47.4 34.7 37.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
352.4B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
331.8B USD 5.5 909 45.1 88.1
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP 5.1 39.1 140.6 225.5
CH
Novartis AG
SIX:NOVN
181.8B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
176.8B CHF 3 15.4 8.8 10.4

See Also

Summary
GLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLS stock valuation using valuation multiples.
Wall Street Estimates
GLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.